Moderna is the standout gainer, but the stragglers are becoming more apparent as the pandemic tide retreats.
Big risers include Eli Lilly, Biogen, Moderna and Biontech.
New findings for IL-6 blockade in the Recovery trial finally confirm a signal. Can pending pandemic readouts for other mechanisms do the same?
Myovant and Pfizer showed that deal-making was not taking a Christmas break, but for Celgene CVR holders the dream is almost over. And vaccine approvals gained pace.
It is vital that the first authorised at-home, non-prescription Covid-19 antigen test be used in the right way.
A new UK plan to use antigen tests for wide-scale screening for Covid-19 may not be the easy win the government is seeking.
The $13.1bn price suggests that Bristol could be banking on mavacamten’s potential outside rare diseases.
LY-CoV555 shows promising signs for the antibody approach, with Regeneron not far behind.